Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline response prediction using motor cortex magnetic brain stimulation in major depressive disorder
IRCT20100119003106N44Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of sertraline in major depressive disorder (MDD), sponsored by Islamic Azad University. Primary endpoint: Response rate to sertraline. Started May 2022; status: completed.
02
Drugs
sertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20100119003106N44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100119003106N44.